Inhibition of PAI-1 may prevent CKD progression and is likely to stimulate its regression
This might seem counterintuitive if you've heard otherwise, but it highlights the complexity of nutritional science
User reports consistently describe the combination as more effective than either peptide individually
Similarly, lepodisiran has shown well-tolerated and dose-dependent reductions in serum Lp(a) concentrations, with a Phase III trial currently recruiting participants and expected to be completed by 2029 (NCT06292013 and NCT04914546)
[DOI] [PMC free article] [PubMed] [Google Scholar] 111.Klebanov G.I., Teselkin Y.O., Babenkova I.V., Popov I.N., Levin G., Tyulina O.V., Boldyrev A.A., Vladimirov Y.A